Conference Co-Chairpersons
June M. Chan, University of California – San Francisco, San Francisco, CA
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA

The AACR and the Prostate Cancer Foundation were pleased to offer this conference to discuss the latest advances in prostate cancer research. The conference attracted nearly 300 investigators and 150 abstract submissions and featured presentations from thought-leaders in the fields of androgen signaling, exercise, genetic susceptibility, metabolism, modeling, obesity, precision medicine, prevention, and resistance. The program featured a mix of plenary sessions, keynote lectures, a point/counterpoint session, short talks from highly rated abstracts, and poster sessions.

The AACR and the Prostate Cancer Foundation would like to thank the following organizations for their generous support of this conference.

Professional Educational Grants

---

The AACR and the Prostate Cancer Foundation thank the following organizations for their generous support of the travel awards provided at this conference.

Award Supporters

---

The AACR and the Prostate Cancer Foundation thank the following organizations for their generous support of the travel awards provided at this conference.

---
Saturday, January 18

7:00 p.m.-9:00 p.m.  Opening Plenary Session

Targeting PI3K for cancer therapy*
Lewis C. Cantley, The Cancer Center at Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY

Prostate cancer epidemiology in the PSA era: The imperative to focus on lethal disease*
Meir J. Stampfer, Harvard School of Public Health, Boston, MA

9:00 p.m.-10:30 p.m.  Opening Reception

Sunday, January 19

7:00 a.m.-8:00 a.m.  Continental Breakfast

8:00 a.m.-10:00 a.m.  Plenary Session 1: Obesity, Exercise, Metabolism, and Aggressive Prostate Cancer
Chairperson: June M. Chan, University of California – San Francisco, San Francisco, CA

Metabolic aspects of prostate cancer*
Michael N. Pollak, Jewish General Hospital, Montreal, QC, Canada

Obesity, its sequelae, and prostate cancer risk and outcomes
Elizabeth A. Platz, Johns Hopkins University, Baltimore, MD

The role of metabolism in prostate cancer*
Matthew G. Vander Heiden, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA

10:00 a.m.-10:30 a.m.  Break

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.
10:30 a.m.-12:30 p.m.  Plenary Session 2: Can Prostate Cancer be Prevented?
Chairperson: Peter H. Gann, University of Illinois at Chicago, Chicago, IL

Forging ahead with prostate cancer prevention*
Peter H. Gann

Chemopreventive agent development for prostate cancer: Is there a future?*
Maarten C. Bosland, University of Illinois, Chicago, IL

Fish oil, omega-3 fatty acids, and prostate cancer
William J. Aronson, University of California – Los Angeles, Los Angeles, CA

Discussant: Meir J. Stampfer, Harvard School of Public Health, Boston, MA

12:30 p.m.-2:30 p.m.  Lunch Break (lunch on your own)
(Poster set-up and viewing available.)

2:30 p.m.-4:30 p.m.  Plenary Session 3: Genetic Susceptibility to Prostate Cancer: From Rare to Common Variants
Chairperson: Kathleen A. Cooney, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Rare penetrant prostate cancer genes (BRCA1,2 and HOXB13)
Kathleen A. Cooney

Genetic risk for prostate cancer in racially diverse populations
John S. Witte, University of California – San Francisco, San Francisco, CA

Current status of common prostate cancer risk-associated SNPs and their potential clinical utilities
Jianfeng Xu, Wake Forest School of Medicine, Winston Salem, NC

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
4:45 p.m.-5:25 p.m.  Short Talks from Poster Session A Abstracts

Monitoring copy number aberration dynamics in sequential plasma samples from castration-resistant prostate cancer (CRPC) patients (PR01, A2)
Gerhardt Attard, The Institute of Cancer Research and the Royal Marsden, Sutton, Surrey, United Kingdom

Frequency and characterization of circulating tumor cell (CTC) populations in metastatic castration-resistant prostate cancer (mCRPC) (PR02, A11)
Ryan Dittamore, Epic Sciences, Inc., La Jolla, CA

Development and validation of a lifestyle score for prevention of lethal prostate cancer (PR03, A15)
Stacey A. Kenfield, University of California – San Francisco, San Francisco, CA

Urinary melatonin levels, sleep disruption, and risk of prostate cancer (PR04, A21)
Sarah C. Markt, Harvard School of Public Health, Boston, MA

Coordinate induction of autophagy and apoptosis by wildtype p53 in prostate cancer cells (PR06, A54)
Chris Albanese, Georgetown University Medical Center, Washington, DC

Patient-specific kinase activation patterns in lethal metastatic castration-resistant prostate cancer (PR07, A56)
Justin M. Drake, University of California – Los Angeles, Los Angeles, CA

5:30 p.m.-7:30 p.m.  Poster Session A

Monday, January 20

7:00 a.m.-8:00 a.m.  Continental Breakfast

8:00 a.m.-10:00 a.m.  Plenary Session 4: Precision Medicine: Decision to Treat or Not Treat
Chairperson: Peter R. Carroll, University of California - San Francisco, San Francisco, CA

Prostate cancer: To treat or not to treat – Why is this is an important question?
Peter R. Carroll

The end of overtreatment: Genomics in the selection of men for active surveillance
Eric A. Klein, The Cleveland Clinic Lerner Research Institute, Cleveland, OH

Can biomarkers guide decisions about active surveillance versus immediate treatment?
Matthew R. Cooperberg, University of California – San Francisco, San Francisco, CA

Long noncoding RNAs: What you didn’t learn during your postdoc
Felix Y. Feng, University of Michigan, Ann Arbor, MI

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
10:00 a.m.-10:20 a.m.  Break (with poster set-up and viewing)

10:20 a.m.-12:20 p.m.  Plenary Session 5: Toward Better Models of Prostate Cancer

Chairperson: Owen Witte, University of California – Los Angeles, Los Angeles, CA

Starting and stopping prostate cancer in stem cells *
Owen N. Witte

Using cross-species analysis of genome-wide regulatory networks to identify drivers of prostate cancer malignancy *
Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY

Using MYC overexpression and PTEN loss in mouse models of prostate cancer
Angelo M. De Marzo, The Johns Hopkins University School of Medicine, Baltimore, MD

Title to be announced
Peter Kuhn, The Scripps Research Institute, LaJolla, CA

12:20 p.m.-12:55 p.m.  Short Talks from Poster Session B Abstracts

A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer (PR08, B2)
Akash Patnaik, Beth Israel Deaconess Medical Center, Boston, MA

Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells (PR09, B20)
Tanya I. Stoyanova, University of California – Los Angeles, Los Angeles, CA

CpG-STAT3 siRNA for therapy of castration-resistant prostate cancers (PR10, B35)
Marcin Kortylewski, City Of Hope, Duarte, CA

Immune evasion strategies of neuroendocrine-like enzalutamide-resistant prostate cancer (PR11, B44)
Jennifer L. Bishop, Vancouver Prostate Centre, Vancouver, BC, Canada.

Mechanisms of clonal progression from Gleason 3 to Gleason 4 prostate cancer (PR12, B57)
Adam G. Sowalsky, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

1:00 p.m.-3:00 p.m.  Poster Session B (and lunch)

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
3:00 p.m.-5:00 p.m. Plenary Session 6: Anti-Androgen Sensitivity and Resistance During Prostate Cancer Progression
Chairperson: Nima Sharifi, The Cleveland Clinic, Cleveland, OH

Opening the floodgates to DHT synthesis sustains resistance to androgen depletion*
Nima Sharifi

Epigenetic targets in castration-resistant prostate cancer
Myles A. Brown, Dana-Farber Cancer Institute, Boston, MA

AR-DNA repair interplay in prostate cancer: Mechanisms and implications for disease progression*
Karen E. Knudsen, Thomas Jefferson University/Kimmel Cancer Center, Philadelphia, PA

Emerging developments in abiraterone resistance*
Steven P. Balk, Beth Israel Deaconess Medical Center, Boston, MA

5:05 p.m.-6:05 p.m. Point/Counter-Point Session: Can Treatment Targeted at the Androgen Signaling Pathway Ever Cure Prostate Cancer?
Moderator: Eric Small, University of California – San Francisco, San Francisco, CA

Panelists:
Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX
Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA

Tuesday, January 21

7:00 a.m.-8:00 a.m. Continental Breakfast

8:00 a.m.-10:00 a.m. Plenary Session 7: Precision Medicine: How Much Can We Further Personalize Prostate Cancer Treatment?
Chairperson: Himisha Beltran, Weill Cornell Medical College of Cornell University, New York, NY

Grasping the tails of precision medicine
Himisha Beltran

Towards precision medicine for advanced prostate cancer*
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

Precision medicine: How much can we further personalize prostate cancer treatment?
Eric Small, University of California – San Francisco, San Francisco, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
10:00 a.m.-10:15 a.m.    Break

10:15 a.m.-11:15 a.m.    Closing Plenary Session

Prostate cancer landscape 2014: The emperor of all research opportunities*
Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA

11:15 a.m.    Departure

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.